Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of “Moderate Buy” by Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $9.00.

Several research firms recently weighed in on PYXS. Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target for the company. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 target price (down from $10.00) on shares of Pyxis Oncology in a research report on Friday, December 20th. William Blair cut shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday, November 21st. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective (down from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS opened at $1.40 on Friday. Pyxis Oncology has a 1 year low of $1.38 and a 1 year high of $6.85. The company has a market capitalization of $83.26 million, a PE ratio of -1.36 and a beta of 1.06. The business has a fifty day moving average price of $1.62 and a two-hundred day moving average price of $2.88.

Insider Buying and Selling

In other Pyxis Oncology news, CFO Pamela Ann Connealy bought 88,850 shares of Pyxis Oncology stock in a transaction that occurred on Tuesday, November 26th. The stock was acquired at an average cost of $1.96 per share, for a total transaction of $174,146.00. Following the completion of the transaction, the chief financial officer now directly owns 1,199,143 shares in the company, valued at $2,350,320.28. This represents a 8.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 9.80% of the stock is currently owned by insiders.

Institutional Trading of Pyxis Oncology

Large investors have recently modified their holdings of the business. Intech Investment Management LLC bought a new position in shares of Pyxis Oncology in the third quarter worth approximately $55,000. SG Americas Securities LLC bought a new position in shares of Pyxis Oncology in the 3rd quarter worth $58,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at $65,000. MetLife Investment Management LLC lifted its holdings in shares of Pyxis Oncology by 41.1% during the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock worth $69,000 after acquiring an additional 5,484 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in Pyxis Oncology in the third quarter worth $107,000. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.